CCDC102B and triple-negative breast carcinoma: When these tumors were divided into luminal A, luminal B, HER2+ and triple-negative breast cancer (TNBC) subtypes, high expression of CCDC102B showed a particularly strong correlation with poor clinical outcome in HER2+ and TNBC (Supplementary Figures 2E, F).